Companion Diagnostics (CDx) Development Market Size, Share, Growth Factors, Competitive Landscape, with Regional Forecast to 2035
This report presents a detailed, data-driven analysis of the global Companion Diagnostics (CDx) Development Market size, offering insights into historical performance, current dynamics, and projections from 2025 to 2035. With a strong emphasis on factual assessment, the report refrains from speculative assumptions and aims to support business decisions through accurate forecasting and strategic intelligence.
I recently came across a report by Roots Analysis that really put things into perspective. According to them, The companion diagnostics (CDx) development market, valued at USD 892 million in 2025, is projected to reach USD 779 million in 2026 and USD 1,796 million by 2035, with a 9.7% CAGR during the forecast period 2026 to 2035.
Market Segmentation
- Historical Trend: Since 2019
- Base Year: 2025
- Forecast Period: Till 2035
- Current Market Size: USD 779 Million
- Market Size in 2035: USD 1,796 Million
- Growth Rate: ~9.7%
- Type of Service Offered
• Feasibility Studies
• Assay Development
• Analytical Validation
• Clinical Validation
• Manufacturing
- Analytical Technique Used
• NGS
• PCR
• IHC
• Flow Cytometry
• Other Analytical Techniques
- Target Therapeutic Area
• Oncological Disorders
• Non-oncological Disorders
- End User
• Industry Players
• Non- Industry Players
- Key Geographical Region
• North America
• Europe
• Asia-Pacific
- Leading Market Players
• Almac Diagnostics
• BGI Genomics
• Eurofins
• Geneuity Clinical Research Services
• Labcorp
• MEDICAL & BIOLOGICAL LABORATORIES
• Q2 Solutions
• QIAGEN
• Quest Diagnostics
• ResearchDx
- PowerPoint Presentation(Complimentary): Available
- Customization Scope: 15% Free Customization
- Excel Data Packs(Complimentary)
• Market Landscape Analysis (Service Providers)
• Market Landscape Analysis (Companion Diagnostic Products)
• Company Competitiveness Analysis
• Partnership and Collaborations Analysis
• Likely Partner Analysis
• Big Pharma Initiatives
• Market Size and Opportunity Analysis
Read More: https://www.rootsanalysis.com/reports/companion-diagnostics-services/297.html
Key Geographies
North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America
Each segment is analyzed by volume, value, and growth patterns, offering a comparative understanding of usage trends and market opportunities.
Companion Diagnostics (CDx) Development Market Share Insights
▪ Companion Diagnostics (CDx) Development Market: Report Attributes / Market Segmentations
Analytical Insights Covered
▪ Market Landscape Analysis (Service Providers)
▪ Market Landscape Analysis (Companion Diagnostic Products)
▪ Company Competitiveness Analysis
▪ Partnership and Collaborations Analysis
▪ Likely Partner Analysis
▪ Big Pharma Initiatives
▪ Market Size and Opportunity Analysis
Key Players Include:
Andermatt
Bayer
BioSafe Systems
Certis Biologicals
Corteva Agriscience
Novozymes
Nutri-Tech Solutions
ProFarm
Syngenta
Valent Biosciences
These companies are assessed based on their contributions to market share, innovation, and responsiveness to global and regional demand shifts.
Regional Insights
Each region is evaluated based on:
Historical market trends and sales data
Regulatory frameworks
Product availability and distribution strength
Emerging opportunities and constraints
Comparative regional analysis enables better targeting of expansion strategies and investment planning.
This report presents a detailed, data-driven analysis of the global Companion Diagnostics (CDx) Development Market size, offering insights into historical performance, current dynamics, and projections from 2025 to 2035. With a strong emphasis on factual assessment, the report refrains from speculative assumptions and aims to support business decisions through accurate forecasting and strategic intelligence.
I recently came across a report by Roots Analysis that really put things into perspective. According to them, The companion diagnostics (CDx) development market, valued at USD 892 million in 2025, is projected to reach USD 779 million in 2026 and USD 1,796 million by 2035, with a 9.7% CAGR during the forecast period 2026 to 2035.
Market Segmentation
- Historical Trend: Since 2019
- Base Year: 2025
- Forecast Period: Till 2035
- Current Market Size: USD 779 Million
- Market Size in 2035: USD 1,796 Million
- Growth Rate: ~9.7%
- Type of Service Offered
• Feasibility Studies
• Assay Development
• Analytical Validation
• Clinical Validation
• Manufacturing
- Analytical Technique Used
• NGS
• PCR
• IHC
• Flow Cytometry
• Other Analytical Techniques
- Target Therapeutic Area
• Oncological Disorders
• Non-oncological Disorders
- End User
• Industry Players
• Non- Industry Players
- Key Geographical Region
• North America
• Europe
• Asia-Pacific
- Leading Market Players
• Almac Diagnostics
• BGI Genomics
• Eurofins
• Geneuity Clinical Research Services
• Labcorp
• MEDICAL & BIOLOGICAL LABORATORIES
• Q2 Solutions
• QIAGEN
• Quest Diagnostics
• ResearchDx
- PowerPoint Presentation(Complimentary): Available
- Customization Scope: 15% Free Customization
- Excel Data Packs(Complimentary)
• Market Landscape Analysis (Service Providers)
• Market Landscape Analysis (Companion Diagnostic Products)
• Company Competitiveness Analysis
• Partnership and Collaborations Analysis
• Likely Partner Analysis
• Big Pharma Initiatives
• Market Size and Opportunity Analysis
Read More: https://www.rootsanalysis.com/reports/companion-diagnostics-services/297.html
Key Geographies
North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America
Each segment is analyzed by volume, value, and growth patterns, offering a comparative understanding of usage trends and market opportunities.
Companion Diagnostics (CDx) Development Market Share Insights
▪ Companion Diagnostics (CDx) Development Market: Report Attributes / Market Segmentations
Analytical Insights Covered
▪ Market Landscape Analysis (Service Providers)
▪ Market Landscape Analysis (Companion Diagnostic Products)
▪ Company Competitiveness Analysis
▪ Partnership and Collaborations Analysis
▪ Likely Partner Analysis
▪ Big Pharma Initiatives
▪ Market Size and Opportunity Analysis
Key Players Include:
Andermatt
Bayer
BioSafe Systems
Certis Biologicals
Corteva Agriscience
Novozymes
Nutri-Tech Solutions
ProFarm
Syngenta
Valent Biosciences
These companies are assessed based on their contributions to market share, innovation, and responsiveness to global and regional demand shifts.
Regional Insights
Each region is evaluated based on:
Historical market trends and sales data
Regulatory frameworks
Product availability and distribution strength
Emerging opportunities and constraints
Comparative regional analysis enables better targeting of expansion strategies and investment planning.
Companion Diagnostics (CDx) Development Market Size, Share, Growth Factors, Competitive Landscape, with Regional Forecast to 2035
This report presents a detailed, data-driven analysis of the global Companion Diagnostics (CDx) Development Market size, offering insights into historical performance, current dynamics, and projections from 2025 to 2035. With a strong emphasis on factual assessment, the report refrains from speculative assumptions and aims to support business decisions through accurate forecasting and strategic intelligence.
I recently came across a report by Roots Analysis that really put things into perspective. According to them, The companion diagnostics (CDx) development market, valued at USD 892 million in 2025, is projected to reach USD 779 million in 2026 and USD 1,796 million by 2035, with a 9.7% CAGR during the forecast period 2026 to 2035.
Market Segmentation
- Historical Trend: Since 2019
- Base Year: 2025
- Forecast Period: Till 2035
- Current Market Size: USD 779 Million
- Market Size in 2035: USD 1,796 Million
- Growth Rate: ~9.7%
- Type of Service Offered
• Feasibility Studies
• Assay Development
• Analytical Validation
• Clinical Validation
• Manufacturing
- Analytical Technique Used
• NGS
• PCR
• IHC
• Flow Cytometry
• Other Analytical Techniques
- Target Therapeutic Area
• Oncological Disorders
• Non-oncological Disorders
- End User
• Industry Players
• Non- Industry Players
- Key Geographical Region
• North America
• Europe
• Asia-Pacific
- Leading Market Players
• Almac Diagnostics
• BGI Genomics
• Eurofins
• Geneuity Clinical Research Services
• Labcorp
• MEDICAL & BIOLOGICAL LABORATORIES
• Q2 Solutions
• QIAGEN
• Quest Diagnostics
• ResearchDx
- PowerPoint Presentation(Complimentary): Available
- Customization Scope: 15% Free Customization
- Excel Data Packs(Complimentary)
• Market Landscape Analysis (Service Providers)
• Market Landscape Analysis (Companion Diagnostic Products)
• Company Competitiveness Analysis
• Partnership and Collaborations Analysis
• Likely Partner Analysis
• Big Pharma Initiatives
• Market Size and Opportunity Analysis
Read More: https://www.rootsanalysis.com/reports/companion-diagnostics-services/297.html
Key Geographies
North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America
Each segment is analyzed by volume, value, and growth patterns, offering a comparative understanding of usage trends and market opportunities.
Companion Diagnostics (CDx) Development Market Share Insights
▪ Companion Diagnostics (CDx) Development Market: Report Attributes / Market Segmentations
Analytical Insights Covered
▪ Market Landscape Analysis (Service Providers)
▪ Market Landscape Analysis (Companion Diagnostic Products)
▪ Company Competitiveness Analysis
▪ Partnership and Collaborations Analysis
▪ Likely Partner Analysis
▪ Big Pharma Initiatives
▪ Market Size and Opportunity Analysis
Key Players Include:
Andermatt
Bayer
BioSafe Systems
Certis Biologicals
Corteva Agriscience
Novozymes
Nutri-Tech Solutions
ProFarm
Syngenta
Valent Biosciences
These companies are assessed based on their contributions to market share, innovation, and responsiveness to global and regional demand shifts.
Regional Insights
Each region is evaluated based on:
Historical market trends and sales data
Regulatory frameworks
Product availability and distribution strength
Emerging opportunities and constraints
Comparative regional analysis enables better targeting of expansion strategies and investment planning.
0 Commentarios
0 Acciones
35 Views
0 Vista previa